ESR1 and breast carcinoma: Furthermore, kinase fusions in breast cancer analyzed by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets seemed to be enriched in hormone-resistant, metastatic carcinomas and mutually exclusive with ESR1 mutations [50].